Last updated on January 2020

A Study of Atezolizumab (Anti Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck


Brief description of study

This study will evaluate the efficacy and safety of atezolizumab compared with placebo as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck (SCCHN)

Clinical Study Identifier: NCT03452137

Find a site near you

Start Over

Adelaide Cancer Centre

Kurralta Park, Australia
5.08miles
  Connect »